News & research updates

Factor Therapeutics has developed a list of Frequently Asked Questions (FAQs) to help answer shareholders’ queries about the results of the…

Factor Therapeutics held a conference call for investors on Wednesday 14 November. Please find the presentation slides shared during the call…

Factor Therapeutics today announced the results of its Phase 2 clinical trial, VF00102. Please find more information here.

Factor Therapeutics announced the appointment of its transaction advisor. Please find more information here.

Treatment completion marks milestone in Phase 2 clinical trial An important milestone in Factor Therapeutics’ Phase 2 clinical trial for venous…

Factor Therapeutics provides its quarterly activity update to shareholders. Please see the full update here.

Factor Therapeutics announced the final patient has been recruited into its Phase 2 clinical trial VF00102. Please find more information here.

Factor Therapeutics announced that screening in its Phase 2b clinical trial, VF00102, will close this week, marking the final step before…

Factor Therapeutics announced that successful completion and readout are on track in the Phase 2b clinical trial, VF00102, with recruitment expected…

Factor Therapeutics met with potential partners and collaborators at the Symposium on Advanced Wound Care (SAWC) Spring meeting in Charlotte, NC…